- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04432428
Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty (Zalviso)
The sufentanil sublingual tablet system (SSTS) is an innovative patient-controlled analgesia (PCA) device for the management of acute moderate to severe postoperative pain in hospital settings in adult patients.
The SSTS is non-invasive and imposes no restrictions on patient mobility, which renders it particularly suitable for clinical conditions where early mobilization is a key component of successful surgical outcome.
The present study tests the hypothesis that SSTS is an efficient and safe analgesic technique allowing fast track rehabilitation after total knee arthroplasty in a prospective cohort design.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Total knee arthroplasty is one of the most common major procedures performed today with a significant impact on health care budgets. Fast track rehabilitation programmes are being developed to control hospitalization costs associated with this procedure. Interestingly, such pathway controlled fast track programs also appear to enhance functional recovery and to reduce complications. These beneficial effects are mainly attributed to the practice of rapid mobilization and early intensified physiotherapy which can only be achieved with effective analgesic techniques.
Current PCA techniques - predominantly morphine based - are the gold standard for this purpose but they involve intravenous access and a programmable computer system requiring close supervision. Reported shortcomings are systems failure leading to analgesic gaps, drug errors and restrictions in mobility since patients are tethered to IV poles. The SSTS may overcome these limitations because the opioid used, sufentanil, has a more predictable time of onset, the delivery system does not require programming, and the device does not limit patient's mobility. It retains the benefits of potent analgesia as well as patient empowerment and is particularly suited to target the analgesic effect precisely to the level required in physiotherapeutic sessions.
The present study will test the hypothesis that SSTS is an efficient and safe analgesic technique allowing fast track rehabilitation after total knee arthroplasty in a prospective cohort design.
The study will focus on the efficiency of STSS which is defined as 75% or more of the treated patients proves NRS score less than 4 during 48 hours postoperatively, additionally to the basic pain treatment (paracetamol and NSAID).
The STSS will allow the patient tot take a maximum of 3 doses in one hour. Treatment with the STSS is continued over a period of 48 hours or if necessary up to 72 hours.
During this period the patients pain en parameters will be monitored closely.
The maximum administered total dose of Zalviso will not exceed 1.2mg.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgium, 9000
- University Hospital Ghent
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients between 40-75 years old
- Able to give consent
- Scheduled of elective knee arthroplasty with a fast rehabilitation program
- Able to understand PCA principle and capable to operate SSTS device
Exclusion Criteria:
- Outside age range
- Contra indication for anti-inflammatory drugs
- Revision total knee arthroplasty
- history of substance abuse,
- pregnancy,lactation
- severe hepatic impairment (INR>1,5 and/or AST/ALT above x3 highest normal value),
- sleep apnea (documented by sleep laboratory study),
- severe chronic kidney disease (eGFR<30 mL/min/1.73 m2),
- severe and very severe COPD (GOLD III and IV)
- opioid tolerance (use of >15mg oral morphine equivalent per day within the past 3 months),
- chronic pain conditions necessitating gabapentinoids, steroids or anti-inflammatory drugs
- hypersensitivity to sufentanil
- significant respiratory depression (need for outpatient supplemental oxygen therapy),
- participation in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sufentanil sublingual tablet
sufentanil sublingual 15µg tablets
|
all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition. max dose per hour : 3 tablets of 15µg sufentanil |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total time NRS<4
Time Frame: from end of surgery until 48 hours postoperatively
|
cumulative time that patient had NRS<4
|
from end of surgery until 48 hours postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
length of hospital stay
Time Frame: from hospital admission until hospital discharge, up to 1 week post-operatively
|
amount of days that patient was admitted to the hosptial
|
from hospital admission until hospital discharge, up to 1 week post-operatively
|
Incidence of the side effect nausea
Time Frame: from end of surgery until 72 hours postoperatively
|
Incidence of the side effect nausea with a simple scale (none, mild, moderate, severe)
|
from end of surgery until 72 hours postoperatively
|
Incidence of the side effect vomiting
Time Frame: from end of surgery until 72 hours postoperatively
|
Incidence of the side effect vomiting with a simple scale (none, mild, moderate, severe)
|
from end of surgery until 72 hours postoperatively
|
Incidence of the side effect itching
Time Frame: from end of surgery until 72 hours postoperatively
|
Incidence of the side effect itching with a simple scale (none, mild, moderate, severe)
|
from end of surgery until 72 hours postoperatively
|
Incidence of the side effect drowsiness
Time Frame: from end of surgery until 72 hours postoperatively
|
Incidence of the side effect drowsiness with a simple scale (none, mild, moderate, severe)
|
from end of surgery until 72 hours postoperatively
|
Incidence of the side effect constipation
Time Frame: from end of surgery until 72 hours postoperatively
|
Incidence of the side effect constipation with a simple scale (none, mild, moderate, severe)
|
from end of surgery until 72 hours postoperatively
|
Oxygen desaturation
Time Frame: from end of surgery until 72 hours postoperatively
|
Oxygen desaturation
|
from end of surgery until 72 hours postoperatively
|
patient satisfaction with Zalviso PCA
Time Frame: after discontinuation of study medication, up to 72 hrs after start of the study medication
|
patient satisfaction assessed with patient ease of care questionnaire
|
after discontinuation of study medication, up to 72 hrs after start of the study medication
|
health care worker satisfaction with the patients pain treatment with Zalviso PCA
Time Frame: after patients discontinuation of study medication, up to 1 week after stop study medication
|
health care worker satisfaction assessed with nurse/physical therapist ease of care questionnaire
|
after patients discontinuation of study medication, up to 1 week after stop study medication
|
consumption of study medication
Time Frame: from start administration of study medication until end of administration of study medication, up to a maximum of 72 hrs
|
total amount of study medication that was administered
|
from start administration of study medication until end of administration of study medication, up to a maximum of 72 hrs
|
Level of analgesia during physiotherapy
Time Frame: from start until end of physiotherapy session, up to 2 days post-operatively
|
Level of analgesia during physiotherapy assessed with NRS scale
|
from start until end of physiotherapy session, up to 2 days post-operatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Patrick Wouters, MD PhD, University Hospital, Ghent
- Principal Investigator: Luc Verbacnk, MD, Yperman Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Sufentanil
Other Study ID Numbers
- 2019/1741
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Pain
-
Dr. Negrin University HospitalRecruitingPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
-
Hospital of South West JutlandNovo Nordisk A/SNot yet recruitingPhysical Activity | Postoperative Pain, Acute | Postoperative Pain, Chronic | Bariatric Surgery | MobilizationDenmark
-
University of ManitobaUnknown
Clinical Trials on Sufentanil Sublingual Tablet
-
Stallergenes GreerCompletedPrimary DiseaseFrance, Italy, Spain
-
Stallergenes GreerCompletedAllergic Rhinitis Due to Grass PollensUnited States
-
Stallergenes GreerCompleted
-
Stallergenes GreerCompletedSeasonal Allergic RhinitisAustria
-
ALK-Abelló A/SActive, not recruitingAllergic Rhinitis Due to Dermatophagoides Farinae | Allergic Rhinitis Due to Dermatophagoides Pteronyssinus | Allergic Rhinitis Due to House Dust MiteSpain, Russian Federation, United States, Poland, Bulgaria, Canada, France, Germany, Lithuania, Slovakia, Ukraine
-
ALK-Abelló A/STerminatedAllergic RhinoconjunctivitisAustria, China
-
Bispebjerg HospitalLund University; University of Copenhagen; ALK-Abelló A/SCompletedThe Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma (VITAL)Allergic Asthma Due to Dermatophagoides PteronyssinusDenmark
-
AcelRx Pharmaceuticals, Inc.U.S. Army Medical Research and Development CommandCompletedModerate-to-severe Acute PainUnited States
-
Simcere Pharmaceutical Co., LtdCompleted
-
Centre Hospitalier Universitaire de TivoliCompletedPostoperative PainBelgium